¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumour necrosis factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • scatter factor
    »ê¶õ°è¼ö
  • stroma factor
    ¹öÆÀÁúÀÎÀÚ, °£ÁúÀÎÀÚ
  • sunprotective factor
    Àϱ¤º¸È£Áö¼ö
  • sebotropic factor
    Áö·çÃËÁøÀÎÀÚ
  • safety factor
    ¾ÈÀü°è¼ö
  • skin vascular permeability factor
    ÇǺÎÇ÷°üÅõ°úÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • vascular permeability factor
    Ç÷°üÅõ°úÀÎÀÚ
  • virulence factor
    µ¶¼ºÀÎÀÚ, ¹ßº´ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • decay-accelerating factor(daf)
    Decay-accelerating factor(DAF)
  • dermonecrotic factor
    ÇǺα«»çÀÎÀÚ
  • diabetogenic factor
    ´ç´¢À¯¹ßÀÎÀÚ.
  • differentiation factor
    °¨º°¿äÀÎ, °¨º°¿ä¼Ò, °¨º°ÀÎÀÚ
  • dilution factor
    ¹±ÈûÀÎÀÚ(ÊÙËöËö), Èñ¼®ÀÎÀÚ.
  • dilution factor
    ¹±ÈûÀÎÀÚ(¡­ì×í­), Èñ¼®ÀÎÀÚ.
  • dose conversion factor
    ¼±·®º¯È¯°è¼ö
  • dose limiting factor
    ¼±·®ÇѵµÀÎÀÚ, ¼±·®Á¦ÇÑÀÎÀÚ
  • dose modifying factor
    ¼±·®¼ö½Ä°è¼ö
  • dose-reduction factor
    ¼±·®°¨¼Ò°è¼ö
  • drug resistance factor
    ¾àÁ¦³»¼ºÀÎÀÚ
  • drug resistance transfer factor
    ¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
  • duplicate factor
    Áߺ¹ÀÎÀÚ.
  • early pregnancy factor(EPF)
    ÃʱâÀÓ½ÅÀÎÀÚ
  • edaphic factor
    ÅäÁöÀÎÀÚ(ÊÙËöËö).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • Stuart factor
    ½ºÆ©¾Æ¸£Æ® ÀÎÀÚ(ì×í­)
  • sulfation factor
    Ȳ»êÈ­ ÀÎÀÚ (üÜß«ûùì×í­)
  • surface factor
    Ç¥¸éÀÎÀÚ (øúØüì×í­)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
  • termination factor
    Á¾·áÀÎÀÚ (ðûÖõì×í­)
  • T factor
    T ÀÎÀÚ (ì×í­)
  • third factor
    Á¦»ïÀÎÀÚ (ð¯ß²ì×í­)
  • three-factor cross
    »ïÀÎÀÚ ±³Â÷ (ß²ì×í­Îßó©)
  • thymic humoral factor
    Èä¼± ü¾×ÀÎÀÚ (ýØàÊô÷äûì×í­)
  • thymidine factor
    ŸÀ̵̹ò ÀÎÀÚ (ì×í­)
  • thyrotropic hormone releasing factor
    °©»ó¼±ÀÚ±Ø(Ë£ßÒàÍí©Ð½) È£¸£¸ó À¯¸®ÀÎÀÚ(ë´×îì×í­)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • tissue factor
    Á¶Á÷ÀÎÀÚ (ðÚòÄì×í­)
  • transfer factor
    "ÀüÀÌ(ï®ì¹) ÀÎÀÚ(ì×í­), Àü´ÞÀÎÀÚ(îîÓ¹ì×í­)"
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
HN head and neck; head nurse; hemagglutinin neuraminidase; hematemesis neonatorum; hemorrhage of newbor...
IAN idiopathic aseptic necrosis; indole acetonitrile
IBSN infantile bilateral striated necrosis
INB internuclear bridging; ischemic necrosis of bone
IPN infantile polyarteritis nodosa; infectious pancreatic necrosis [of trout]; intern progress note; int...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
TRAF Factor Receptor-associated factor
FVIII-vWF Factor VIII-von Willebrand Factor
Factor Xa Factor X
GM-CSF Granulocyte colony-stimulating factor , granulocyte-macrophage colony-stimulating factor
G-CSF Granulocyte-Macrophage Colony-Stimulating Factor , Granulocyte Colony-Stimulating Factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • vitamin B12-intrinsic factor
    ºñŸ¹Î B12-³»Àμº ÀÎÀÚ
  • wall correction factor
    º®±³Á¤ °è¼ö
  • wedge factor
    ½û±â ÀÎÀÚ
  • weighting factor
    °¡Áß°è¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
hylic tumour <tumour> A neoplasm of pulp tissue, resulting from proliferation of elements derived from the embryonic pulp of epiblastic origin.
Synonym: hylic tumour.
Origin: G. Hyle, stuff, crude matter, + -oma, tumour
(05 Mar 2000)
smooth muscle tumour A tumour composed of smooth muscle tissue, as opposed to leiomyoma, a tumour derived from smooth muscle.
(12 Dec 1998)
solid tumour A cancer that originates in organ or tissue other than bone marrow or the lymph system.
(16 Dec 1997)
solitary fibrous tumour A benign tumour of fibrous tissue which usually arises in the pleural space on other sites.
Synonym: benign mesothelioma.
(05 Mar 2000)
spinal cord tumour A spinal cord tumour is a aggregate if cells that form a mass that can compress the spinal cord. Spinal cord tumours may arise from local structures (for example meninges) or from a cancer from a distant site (i.e. Metastasis). Regardless of the aetiology, all spinal cord tumours cause symptoms from compression on the spinal cord, surrounding nerve roots or blood vessels that supply the cord. Symptoms are variable with the extent and the level of the spinal cord tumour. Common symptoms include back pain that may radiate, numbness and tingling to the lower extremities, muscle weakness in the legs, difficulty walking and loss of bowel and bladder control (incontinence).
(27 Sep 1997)
spinal tumour A spinal cord tumour is a aggregate if cells that form a mass that can compress the spinal cord. Spinal cord tumours may arise from local structures (for example meninges) or from a cancer from a distant site (i.e. Metastasis). Regardless of the aetiology, all spinal cord tumours cause symptoms from compression on the spinal cord, surrounding nerve roots or blood vessels that supply the cord. Symptoms are variable with the extent and the level of the spinal cord tumour. Common symptoms include back pain that may radiate, numbness and tingling to the lower extremities, muscle weakness in the legs, difficulty walking and loss of bowel and bladder control (incontinence).
(27 Sep 1997)
squamous odontogenic tumour A benign epithelial odontogenic tumour thought to arise from the epithelial cell rests of Malassez; appears clinically as a radiolucent lesion closely associated with the tooth root and histologically as islands of squamous epithelium enclosed by a peripheral layer of flattened cells.
(05 Mar 2000)
Nelson tumour A pituitary tumour causing the symptoms of Nelson syndrome.
(05 Mar 2000)
neuroectodermal tumour, melanotic A benign, rapidly growing, deeply pigmented tumour of the jaw and occasionally of other sites, consisting of an infiltrating mass of cells arranged in an alveolar pattern, and occurring almost exclusively in infants. Its source of origin is in dispute, the various theories giving rise to its several names.
(12 Dec 1998)
neuroectodermal tumour, peripheral A heterogeneous group of malignant neoplasms arising in either supportive structures or neuronal tissue. They occur in adolescents and young adults. This tumour shares a number of characteristics with ewing's sarcoma: it is highly cellular and consists of a monotonous pattern of primitive-appearing round cells. The chest wall is the most common site but the trunk, abdomen, and pelvis are other primary sites.
(12 Dec 1998)
neuroectodermal tumour, primitive A malignant brain tumour sharing common features and biologic properties with medulloblastoma. Some pathologists and clinicians use the terms interchangeably: they both can disseminate throughout the nervous system and, in some cases, systemically. most lesions arise from the posterior fossa in children under five years of age. The tumour often produces hydrocephalus and symptoms of increased intracranial pressure. Papilledema is often present.
(12 Dec 1998)
sugar tumour A benign clear cell tumour of the lung containing abundant glycogen.
(05 Mar 2000)
debulking of tumour <surgery> The surgical removal of as much of a tumour as is possible, although the surgeon is unable to remove the whole thing.
(09 Oct 1997)
superior pulmonary sulcus tumour <oncology, tumour> Tumour originating from the superior sulcus of the lung that invades all or a portion of the brachial plexus.
(16 Dec 1997)
dermal duct tumour A benign small tumour derived from the intradermal part of eccrine sweat gland ducts occurring often on the head and neck.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á